




Spyre Therapeutics Inc
Rank 200 of 363



The relative strengths and weaknesses of Spyre Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spyre Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Spyre Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 8.4% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	74,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,359
Liabilities, Non-Current	4,743
Other Assets	6,293
Other Compr. Net Income	78
Other Expenses	0
Other Liabilities	0
Other Net Income	2,080
Other Revenues	0
Property and Equipment	2,385
Research and Development	64,600
Selling, General and Administrative Expense	15,734

Output Variable	Value in 1000 USD
Assets	83,183
Liabilities	23,102
Expenses	80,334
Revenues	0
Stockholders Equity	60,081
Net Income	-78,254
Comprehensive Net Income	-78,215
BaseVar	94,388
ECR before Limited Liability	99%
Economic Capital Ratio	230%